中草药治疗先兆流产:更新的系统评价与Meta分析
该系统评价纳入57项随机对照试验共5881例患者,评估中草药或中草药联合西药治疗先兆流产的疗效与安全性。结果显示,与单用西药相比,单用中草药或中草药联合西药可提高孕28周后继续妊娠率、治疗后继续妊娠率、β-hCG水平,并降低中医证候严重程度,但不良妊娠结局和新生儿死亡无显著差异。证据质量低至中等,结论需谨慎解释。
要点
- 中草药单用或联合西药可提高先兆流产患者继续妊娠率。
- 中草药治疗可改善β-hCG水平和中医证候严重程度。
- 对不良妊娠结局和新生儿死亡无显著改善,证据质量低至中等。
核心结论
- 当前证据支持中草药可能作为先兆流产的潜在治疗方法,但需谨慎解释。
研究设计与样本
- 纳入57项随机对照试验,共5881例先兆流产患者。
- 检索数据库从建库至2022年6月30日。
- 由三名评价员独立评估偏倚风险并提取数据,采用RevMan计算风险比和95%置信区间,依据GRADE评估证据质量。
主要发现
- 与单用西药相比,单用中草药提高孕28周后继续妊娠率(RR 1.11;95% CI 1.02至1.21;n=1;中等质量证据)。
- 与单用西药相比,单用中草药提高治疗后继续妊娠率(RR 1.30;95% CI 1.21至1.38;n=10;中等质量证据)。
- 与单用西药相比,单用中草药提高β-hCG水平(SMD 6.88;95% CI 1.74至12.03;n=4)并降低中医证候严重程度(SMD -2.94;95% CI -4.27至-1.61;n=2)。
- 与单用西药相比,中草药联合西药提高孕28周后继续妊娠率(RR 1.21;95% CI 1.16至1.27;n=15;中等质量证据)和治疗后继续妊娠率(RR 1.19;95% CI 1.16至1.23;n=41;中等质量证据)。
- 与单用西药相比,中草药联合西药提高β-hCG水平(SMD 2.27;95% CI 1.72至2.83;n=37)并降低中医证候严重程度(SMD -1.74;95% CI -2.21至-1.27;n=15)。
关键数值与推荐
- 纳入标准为评估中草药或中草药联合西药对比其他治疗先兆流产的随机对照试验。
- 与单用西药相比,中草药联合西药在减少不良妊娠结局方面无显著差异(RR 0.97;95% CI 0.62至1.52;n=8)。
- 与单用西药相比,中草药联合西药在减少新生儿死亡方面无显著差异(RR 0.39;95% CI 0.12至1.21;n=2)。
临床怎么用
- 临床可考虑将中草药或中草药联合西药用于先兆流产,以提高继续妊娠率和改善β-hCG水平。
- 需结合中医证候严重程度个体化用药,并监测β-hCG水平变化。
局限性
- 纳入证据质量低至中等,结果需谨慎解释。
- 部分分析纳入研究数量少(如n=1、n=2),结论稳定性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To conduct an updated systematic review and meta-analysis on the efficacy and safety of Chinese herbal medicine (CHM) for threatened miscarriage. Data Sources: Electronic databases were searched from inception to 30 June 2022. Study Eligibility Criteria: Only randomized controlled trials (RCTs) that assessed the efficacy and safety of CHM or combined CHM and Western medicine (CHM-WM) and compared with other treatments for threatened miscarriage were included for analysis. Methods: Three review authors independently evaluated included studies, assessed the risk of bias and extracted data for meta-analysis (continuation of pregnancy after 28 gestational weeks, continuation of pregnancy after treatment, preterm birth, adverse maternal outcomes, neonatal death, TCM syndrome severity, β-hCG levels after treatment), sensitivity analysis (β-hCG level) and subgroup analysis (TCM syndrome severity, β-hCG level). The risk ratio and 95% confidence interval were calculated by RevMan. Certainty of the evidence was assessed according to GRADE. Results: Overall, 57 RCTs involving 5,881 patients met the inclusion criteria. Compared with WM alone, CHM alone showed significant higher incidence of continuation of pregnancy after 28 gestational weeks (Risk Ratio (RR) 1.11; 95% CI 1.02 to 1.21; n = 1; moderate quality of evidence), continuation of pregnancy after treatment (RR 1.30; 95% CI 1.21 to 1.38; n = 10; moderate quality of evidence), higher β-hCG level (Standardized Mean Difference (SMD) 6.88; 95% CI 1.74 to 12.03; n = 4) and lower Traditional Chinese medicine (TCM) syndrome severity (SMD -2.94; 95% CI -4.27 to -1.61; n = 2). Compared with WM alone, combined CHM-WM showed significant higher incidence of continuation of pregnancy after 28 gestational weeks (RR 1.21; 95% CI 1.16 to 1.27; n = 15; moderate quality of evidence), continuation of pregnancy after treatment (RR 1.19; 95% CI 1.16 to 1.23; n = 41; moderate quality of evidence), higher β-hCG level (SMD 2.27; 95% CI 1.72 to 2.83; n = 37) and lower TCM syndrome severity (SMD -1.74; 95% CI -2.21 to -1.27; n = 15). No significant differences in reducing the adverse maternal outcomes and neonatal death were found in combined CHM-WM compared with WM alone (RR 0.97; 95% CI 0.62 to 1.52; n = 8; RR 0.39; 95% CI 0.12 to 1.21; n = 2). Conclusion: Current evidence supported CHM could be a potential treatment for threatened miscarriage. However, results should be interpreted with caution considering the low to moderate quality of the available evidence. Systematic Review Registration: [https://inplasy.com/inplasy-2022-6-0107/], identifier [INPLASY20220107].
引用
- Xie H, Zhang A, Mou X, et al. Chinese herbal medicine for threatened miscarriage: An updated systematic review and meta-analysis. Front Pharmacol. 2023. PMID: 36865912. doi:10.3389/fphar.2023.1083746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。